FDA clears second fly species for maggot wound therapy, expanding biosurgery options
Tags Enterprise
The FDA has cleared Cuprina Holdings' MediFly Maggots, making Lucilia cuprina (Australian sheep blowfly) the second fly species approved for maggot debridement therapy (MDT). The first approved species, Lucilia sericata (common green bottle fly), has been used since 2004. Cuprina, a Singapore-based company, is now the only company with FDA clearance to sell two species of therapeutic larvae. MDT uses live maggots to clean dead tissue from wounds and has shown effectiveness for diabetic ulcers and other chronic wounds, though robust clinical data is still limited.
Technical significance
The FDA clearance of a second fly species for MDT expands the supply chain for a niche but clinically useful therapy. With Cuprina as the only company holding dual-species clearance, the company is positioned to dominate the global maggot therapy market. The approval also reflects a broader trend of regulatory acceptance of biological therapies that leverage natural organisms for medical applications, which could open doors for other bio-based wound treatment approaches.